Apomorphine inhalation - Vectura
Alternative Names: VR 004; VR 040; VR 400Latest Information Update: 02 Oct 2021
At a glance
- Originator Vectura
 - Class Analgesics; Antiparkinsonians; Aporphines; Catechols; Erectile dysfunction therapies; Heterocyclic compounds; Phenanthrenes; Piperidines; Quinolines; Small molecules; Tetrahydronaphthalenes
 - Mechanism of Action Dopamine receptor agonists
 
- 
          
            
              Orphan Drug Status
              Yes - Parkinson's disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 - Available For Licensing Yes - Parkinson's disease
 
Highest Development Phases
- Discontinued Erectile dysfunction; Female sexual dysfunction; Parkinson's disease
 
Most Recent Events
- 01 Sep 2011 Apomorphine inhalation - Vectura is still available for licensing. http://www.vectura.com
 - 31 Mar 2011 Vectura completes a phase II trial in Parkinson's disease in the UK (EudraCT2005-005120-13)
 - 11 Jun 2010 Vectura's inhaled apomorphine product is still in Phase-II trials for Parkinson's disease in United Kingdom